What is LivaNova's neuromodulation — 3t litigation provision?

LivaNova (LIVN) reported neuromodulation — 3t litigation provision of $0 in Q1 2026.

What does neuromodulation — 3t litigation provision mean?

Reflects the estimated financial liability accrued for legal proceedings specifically related to the 3T product line within the Neuromodulation segment. It serves as a measure of potential legal risk and financial impact from ongoing litigation.

LivaNova LIVN Neuromodulation — 3T litigation provision

Other segment segments

Cardiopulmonary

$15K-97.9%

Similar metrics at other companies

MDTLitigation provision

$28.25M-64.4%

ATROIncrease (Decrease) In Litigation Provision

$0+100%

MCKEstimated Litigation Liability, Noncurrent

$5.09B-9.1%

RCLLitigation provision

$130M—

EAT

EATLitigation provision

$0-100%

SEDGLegal Claims

$3.3M+3,671%

Other financials

Income statement

See full

Revenue$362.3M+14.3%

Gross profit$243.7M+12.7%

Operating income$41.5M-14.7%

Net income$22.3M+107%

EPS (diluted)$0.40+107%

Balance sheet

See full

Cash & equivalents$539.7M-26.9%

Total debt$340.9M-49.7%

Total equity$1.2B+17.1%

Total assets$2.5B-1.7%

Cash flow

See full

Operating cash flow$15.2M-36.5%

CapEx$14.3M+32.4%

Free cash flow$926.0K-93.0%

Valuation

See full

Market cap$4.32B+62.8%

Profitability

See full

Gross margin67.5%-0.5pp

Operating margin13.4%+0.8pp

Net margin-16.1%-18.0pp

FCF margin11.2%-0.2pp

Returns & leverage

See full

Return on equity-17.6%-19.5pp

Debt / equity0.3×-0.4×

Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:LossContingencyAccrualProvision.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's neuromodulation — 3t litigation provision.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is LivaNova's neuromodulation — 3t litigation provision?: LivaNova (LIVN) reported neuromodulation — 3t litigation provision of $0 in Q1 2026.
What does neuromodulation — 3t litigation provision mean?: Reflects the estimated financial liability accrued for legal proceedings specifically related to the 3T product line within the Neuromodulation segment. It serves as a measure of potential legal risk and financial impact from ongoing litigation.